As of Wednesday, Organogenesis Holdings Inc.’s (NASDAQ:ORGO) stock closed at $2.83, up from $2.71 the previous day. While Organogenesis Holdings Inc. has overperformed by 4.43%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ORGO fell by -72.81%, with highs and lows ranging from $10.66 to $2.23, whereas the simple moving average fell by -47.08% in the last 200 days.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
On November 10, 2022, BTIG Research Downgraded Organogenesis Holdings Inc. (NASDAQ: ORGO) to Neutral. A report published by Oppenheimer on August 10, 2022, Downgraded its rating to ‘Perform’ for ORGO. SVB Leerink also rated ORGO shares as ‘Outperform’, setting a target price of $9 on the company’s shares in an initiating report dated January 10, 2020. Credit Suisse Initiated an Outperform rating on August 26, 2019, and assigned a price target of $10. Credit Suisse initiated its ‘Outperform’ rating for ORGO, as published in its report on May 02, 2019. Oppenheimer’s report from April 17, 2019 suggests a price prediction of $11 for ORGO shares, giving the stock a ‘Outperform’ rating. SunTrust also rated the stock as ‘Buy’.
Analysis of Organogenesis Holdings Inc. (ORGO)
Further, the quarter-over-quarter increase in sales is 2.70%, showing a positive trend in the upcoming months.
One of the most important indicators of Organogenesis Holdings Inc.’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 24.40% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.30, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and ORGO is recording 871.35K average volume. On a monthly basis, the volatility of the stock is set at 5.69%, whereas on a weekly basis, it is put at 5.10%, with a gain of 4.81% over the past seven days.
How Do You Analyze Organogenesis Holdings Inc. Shares?
The Drug Manufacturers – Specialty & Generic market is dominated by Organogenesis Holdings Inc. (ORGO) based in the USA. When comparing Organogenesis Holdings Inc. shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 6.21, there is a growth in quarterly earnings of -98.30%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.80%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 42.90% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in ORGO shares?
The recent increase in stakes in ORGO appears to be a result of several institutional investors and hedge funds increasing their positions. BlackRock Fund Advisors’s position in ORGO has increased by 9.53% in the first quarter. The company now owns 9,870,054 shares of the stock, with a value of $32.37 million, following the purchase of 858,451 additional shares during the last quarter. Soleus Capital Management LP made another increased to its shares in ORGO during the first quarter, upping its stake by 2.11%. During the last quarter, the company picked up 137,000 additional shares for a total stake of worth $21.73 million, bringing number of shares owned by the company to 6,626,063.
During the first quarter, The Vanguard Group, Inc. added a 257,796 position in ORGO. Morgan Stanley & Co. LLC sold an additional -0.61 million shares in the last quarter, decreasing its holdings by -17.91%, now holding 2.78 million shares worth $9.11 million. At the end of the first quarter, Federated MDTA LLC increased its ORGO holdings by 0.34% and now holds 2.6 million ORGO shares valued at $8.53 million with the added 8931.0 shares during the period. ORGO shares are owned by institutional investors to the tune of 42.90% at present.